First Tracks Biotherapeutics (HAM:B43) PB Ratio: 2.97 (As of Jul. 13, 2026)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics PB Ratio?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 PB Ratio is 2.97 as of Jul. 13, 2026. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,231 Biotechnology companies, First Tracks Biotherapeutics ranks worse than 53.45% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), First Tracks Biotherapeutics's share price is €32.00. First Tracks Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was €10.76. Hence, First Tracks Biotherapeutics's PB Ratio of today is 2.97.

The historical rank and industry rank for First Tracks Biotherapeutics's PB Ratio or its related term are showing as below:

HAM:B43' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 3.22
Current: 3.22

During the past 2 years, First Tracks Biotherapeutics's highest PB Ratio was 3.22. The lowest was 0.00. And the median was 0.00.

HAM:B43's PB Ratio is ranked worse than
53.45% of 1231 companies
in the Biotechnology industry
Industry Median: 2.93 vs HAM:B43: 3.22

During the past 12 months, First Tracks Biotherapeutics's average Book Value Per Share Growth Rate was -4.50% per year.

Back to Basics: PB Ratio


First Tracks Biotherapeutics  (HAM:B43) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


First Tracks Biotherapeutics PB Ratio Related Terms


First Tracks Biotherapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics PB Ratio Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
PB Ratio
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
PB Ratio 0.00 0.00

HAM:B43 vs ALT, RGNX, MDXG: PB Ratio Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


First Tracks Biotherapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's PB Ratio falls into.


HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

First Tracks Biotherapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=32.00/10.762
=2.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 2.97 mean?
First Tracks Biotherapeutics (HAM:B43) has a PB Ratio of 2.97 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #658 out of 1231 companies in the Biotechnology industry, placing it in the top 53.5%.
Is First Tracks Biotherapeutics' PB Ratio too high?
First Tracks Biotherapeutics' current PB Ratio is 2.97. The Biotechnology industry median PB Ratio is 2.93. First Tracks Biotherapeutics' value of 2.97 is 1.4% above this industry median. Based on the distribution chart, First Tracks Biotherapeutics ranks #658 out of 1231 companies in the Biotechnology industry, which is below the industry midpoint. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' PB Ratio compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #658 out of 1231 companies for PB Ratio. This places First Tracks Biotherapeutics in the lower half of its industry. The industry median PB Ratio is 2.93. First Tracks Biotherapeutics' value of 2.97 is 1.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. First Tracks Biotherapeutics's current PB Ratio of 2.97 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current PB Ratio is 2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current PB Ratio of 2.97. The current PB Ratio is 2.97 and 1.4% above the Biotechnology industry median of 2.93. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current PB Ratio is 2.97 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price